ReviewCancer immunity2013
Database of T cell-defined human tumor antigens: the 2013 update.
Review in Cancer immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471673 (A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer), which is not on this map. Cited by 110 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Who cites it
110 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023Pooled it
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.Genome biology · 2015Pooled it
- Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer.Cancer immunology, immunotherapy : CII · 2015Trial
- PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.The Journal of clinical investigation · 2014Trial
- MHC Attention: Identifying HLA-E presented cancer antigens through deep learning and high-throughput screening.bioRxiv : the preprint server for biology · 2026Article
- Defining the rules of engagement: B cells, antibodies and cancer control.Cellular & molecular immunology · 2026Review
- Liquid biopsy in lung cancer screening: rationale, progress, opportunities and challenges.Clinical and experimental medicine · 2025Review
- Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.Nature communications · 2025Article
- Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.International journal of molecular sciences · 2024Review
- A T-cell antigen atlas for meningioma: novel options for immunotherapy.Acta neuropathologica · 2023Article
- Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy.JCI insight · 2023Article
- Article
- Review
- TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.Genomics, proteomics & bioinformatics · 2023Article
- Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens.International journal of molecular sciences · 2023Article
- A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.International journal of molecular sciences · 2023Article
- Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis.Frontiers in immunology · 2023Article
- TSNAD and TSNAdb: The Useful Toolkit for Clinical Application of Tumor-Specific Neoantigens.Methods in molecular biology (Clifton, N.J.) · 2023Article
- An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- dbPepNeo2.0: A Database for Human Tumor Neoantigen Peptides From Mass Spectrometry and TCR Recognition.Frontiers in immunology · 2022Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plethora of tumor antigens that have been--and are still being--defined required systematization to provide a comprehensive overview of those tumor antigens that are the most relevant targets for cancer immunotherapy approaches. Here, we provide a new update of a peptide database resource that we initiated many years ago. This database compiles all human antigenic peptides described in the literature that fulfill a set of strict criteria needed to ascertain their actual "tumor antigen" nature, as we aim at guiding scientists and clinicians searching for appropriate cancer vaccine candidates (www.cancerimmunity.org/peptide). In this review, we revisit those criteria in light of recent findings related to antigen processing. We also introduce the 29 new tumor antigens that were selected for this 2013 update. Two of the new peptides show unusual features, which will be briefly discussed. The database now comprises a total of 403 tumor antigenic peptides.
Indexed as
Identifiers
23882160PMC3718731W2107123894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.